Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma

BACKGROUND: The aim of the study was to investigate the temporary combination of anti-PD-1 plus targeted therapy followed by single targeted therapy in advanced renal cell carcinoma (RCC) as second-line therapy. METHODS: A total of 17 patients from Fudan University Shanghai Cancer Center (FUSCC) wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Xiaolin, Gu, Weijie, Shi, Guohai, Ye, Dingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185682/
https://www.ncbi.nlm.nih.gov/pubmed/34159088
http://dx.doi.org/10.21037/tau-21-338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185682/
https://www.ncbi.nlm.nih.gov/pubmed/34159088
http://dx.doi.org/10.21037/tau-21-338

Ejemplares similares